JPRN-jRCT2080224020未知3 期
A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort Turbuhaler as an Active Control in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PT010006)
适应症
试验速览
- 阶段
- 3 期
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 40age old 至 <= 80age old（—）
- 性别
- All
入选标准
- •Given their signed written informed consent to participate.
- •-Non-child bearing potential (ie, physiologically incapable of becoming pregnant, including any female who is 2 years post-menopausal); or Child bearing potential, has a negative serum pregnancy test at Visit 1, and agrees to acceptable contraceptive methods used consistently and correctly for the duration of the study.
- •-Subjects with an established clinical history of COPD as defined by the American Thoracic Society (ATS)/European Respiratory Society (ERS), or other local applicable guidelines.
- •-Current or former smokers with a history of at least 10 pack-years of cigarette smoking.
- •-Forced expiratory volume in 1 second (FEV1)/Forced vital capacity (FVC) ratio must be <0.70 and FEV1 must be <80% predicted normal value calculated using NHANES III reference equations (or reference norms applicable to other regions).
- •-Required COPD maintenance therapy:
- •-All Subjects must have been on two or more inhaled maintenance therapies for the management of their COPD for at least 6 weeks prior to Screening. Scheduled SABA and/or scheduled SAMA are considered inhaled maintenance therapies
- •Please refer to the study protocol for the complete inclusion criteria list.
排除标准
- •-Significant diseases or conditions other than COPD, which, in the opinion of the Investigator, may put the subject at risk because of participation in the study or may influence either the results of the study or the subject's ability to participate in the study.
- •-Women who are pregnant or lactating, or are planning to become pregnant during the course of the study, or women of childbearing potential who are not using an acceptable method of contraception.
- •-Subjects, who in the opinion of the Investigator, have a current diagnosis of asthma.
- •-Subjects who have been hospitalized due to poorly controlled COPD within 3 months prior to Visit 1 (Screening) or during the Screening Period
- •-Subjects who have poorly controlled COPD, defined as acute worsening of COPD that requires treatment with oral corticosteroids or antibiotics within 6 weeks prior to Visit 1 (Screening) or during the Screening Period
- •-Immune suppression or severe neurological disorders affecting control of the upper airway or other risk factors that in the opinion of the Investigator would put the subject at substantial risk of pneumonia.
- •-Subjects with a diagnosis of narrow angle glaucoma, who, in the opinion of the Investigator, have not been adequately treated.
- •-Subjects who have a history of hypersensitivity to Beta2-agonists, budesonide or any other corticosteroid components, glycopyrronium or other muscarinic anticholinergics, or any other component of the IMPs.
- •Please refer to the study protocol for the complete inclusion criteria list.
研究者
相似试验
进行中（未招募）
不适用
A one year study of the effect of two drugs (fluticasone propionate and formoterol fumarate) given together compared to either drug given alone, in patients who have a lung disease known as COPD.Chronic Obstructive Pulmonary Disease.MedDRA version: 17.0Level: PTClassification code 10009033Term: Chronic obstructive pulmonary diseaseSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2014-001916-20-HUMylan Pharma UK Ltd1,166
进行中（未招募）
不适用
A one year study of the effect of two drugs (fluticasone propionate and formoterol fumarate) given together compared to either drug given alone, in patients who have a lung disease known as COPD.Chronic Obstructive Pulmonary Disease.MedDRA version: 17.0Level: PTClassification code 10009033Term: Chronic obstructive pulmonary diseaseSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2014-001916-20-SEMylan Pharma UK Ltd1,166
进行中（未招募）
不适用
A one year study of the effect of two drugs (fluticasone propionate and formoterol fumarate) given together compared to either drug given alone, in patients who have a lung disease known as COPD.Chronic Obstructive Pulmonary Disease.MedDRA version: 17.1Level: PTClassification code 10009033Term: Chronic obstructive pulmonary diseaseSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2014-001916-20-DKMylan Pharma UK Ltd1,166
进行中（未招募）
不适用
A one year study of the effect of two drugs (fluticasone propionate and formoterol fumarate) given together compared to either drug given alone, in patients who have a lung disease known as COPD.MedDRA version: 17.0Level: PTClassification code 10009033Term: Chronic obstructive pulmonary diseaseSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersChronic Obstructive Pulmonary DiseaseEUCTR2014-001165-27-BEMylan Pharma UK Ltd1,166
进行中（未招募）
不适用
A one year study of the effect of two drugs (fluticasone propionate and formoterol fumarate) given together compared to either drug given alone, in patients who have a lung disease known as COPD.EUCTR2014-001916-20-SKMylan Pharma UK Ltd1,166